




Curriculum Vitae

* CV must be written in English

Personal Information	
Title (i.e. Pf., Dr., etc.)	Pr
Name (First Name/ Middle Name /Last Name)	Harry Sokol
Degree (i.e. MD, MSc, PhD, etc.)	MD, PhD
Country	France
Affiliation	Sorbonne Université and St Antoine Hospital, APHP
E-mail	harry.sokol@aphp.fr
	
Educational Background	
2013	Habilitation to conduct research, Paris VI University
2008	PhD (Microbiology), Paris XI University, France (Supervisor J. Doré, INRA, France)
2007	MD (Hepatology-Gastroenterology), Paris V University, France
2004	Master's degree (Microbiology), Paris XI University, France
Professional Career	
CURRENT POSITION(S)	
2020 –	Coordinator of the “Paris Center for Microbiome Medicine” (www.fhu-pacemm.fr/)
2020 –	Coordinator of the APHP Fecal Microbiota Transplantation Center
2019 –	Co-director Microbiota, gut & inflammation Lab, CRSA UMRS 938, INSERM/Sorbonne University) & team leader MICALIS institute (INRAE), France
2016 –	Full Professor, Gastroenterology Department, Saint Antoine Hospital (APHP) and Sorbonne University, Paris, France
PREVIOUS POSITIONS	
2011 – 2016	Associate Professor, Gastroenterology Department, Saint Antoine Hospital (APHP) and Sorbonne University, Paris, France
2009 – 2011	Post-doctoral Research Fellow, Ramnik Xavier's laboratory, Harvard Medical School, Boston, USA
2007 – 2009	Assistant Professor, Gastroenterology Department, St Antoine Hospital (APHP), Paris, France
Research Field	
<p>Harry Sokol is an internationally recognized expert in Inflammatory Bowel Disease (IBD) and in gut microbiota fields. He published over 330 papers on these topics in major journals (including Gut, Gastroenterology, Cell Metabolism, Cell Host & Microbe, Nature communication, Nature Medicine). His work on the role of the gut microbiota in IBD pathogenesis led to landmark papers describing the IBD-associated dysbiosis (imbalance in gut microbiota composition) and the role of the pivotal commensal bacteria <i>Faecalibacterium prausnitzii</i> in gut homeostasis and in IBD. Currently, his work focuses on deciphering the gut microbiota-host interactions in health and diseases (particularly IBD), in order to better understand their role in pathogenesis and develop innovative treatments. Harry Sokol is exploring particularly the role of the microbiota in tryptophan and energy metabolism for which he is recipient of two ERC grants. Beside basic science, he is also involved in translational research. He is the current president of the French group of Fecal Microbiota Transplantation (www.gftf.fr) and the head of the APHP Fecal Microbiota Transplantation Center, he coordinated a pilot randomized control trial evaluating Fecal Microbiota Transplantation in Crohn's disease and he is currently coordinating 2 phase III nationwide randomized control trial evaluating this approach in ulcerative colitis and Crohn's disease.</p>	
Main Scientific Publications	
<p>TEN ORIGINAL ARTICLES out of 347 (28 000 citations, h-index = 76, Web of Knowledge); Highly Cited Researchers (Clarivate) in 2020, 2021, 2022, 2023.</p> <p>ORCID number: 0000-0002-2914-1822 (https://orcid.org/0000-0002-2914-1822)</p>	
<p>1. Michaudel C, Danne C, Agus A, [...], Langella P, Sokol H. Rewiring the altered tryptophan metabolism as a novel therapeutic</p>	



- strategy in inflammatory bowel diseases. *Gut*. 2023 Jul;72(7):1296-1307. doi: 10.1136/gutjnl-2022-327337.
2. Danne C, Michaudel C, [...], Sokol H. CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival. *Gut*. 2023 Jun;72(6):1081-1092. doi: 10.1136/gutjnl-2022-326917.
 3. Lamas B, Hernandez-Galan L, [...], Bercik P, Sokol H*, Verdu EF* (* equally contributors). Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. *Sci Transl Med*. 2020 Oct 21;12(566):eaba0624. doi: 10.1126/scitranslmed.aba0624.
 4. Sokol H, Landman C, Seksik P, Berard L, [...], Klatzman D, Marteau P; Saint-Antoine IBD Network, Beaugerie L, Simon T. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. *Microbiome*. 2020 Feb 3;8(1):12. doi: 10.1186/s40168-020-0792-5.
 5. Kong L, Lloyd-Price J, Vatanen T, Seksik P, Beaugerie L, Simon T, Vlamakis H, Sokol H*, Xavier RJ* (* equally contributors). Linking Strain Engraftment in Fecal Microbiota Transplantation With Maintenance of Remission in Crohn's Disease. *Gastroenterology*. 2020 Dec;159(6):2193-2202.e5. doi: 10.1053/j.gastro.2020.08.045.
 6. Laurans L, Venteclef N, Haddad Y, [...], Burcelin R, Launay JM, Tedgui A, Mallat Z, Sokol H, Taleb S. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. *Nat Med*. 2018 Aug;24(8):1113-1120. doi: 10.1038/s41591-018-0060-4.
 7. Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, Michel ML, Chong-Nguyen C, Roussel R, Straube M, Jegou S, McQuitty C, Le Gall M, da Costa G, Lecornet E, Michaudel C, Modoux M, Glodt J, Bridonneau C, Sovran B, Dupraz L, Bado A, Richard ML, Langella P, Hansel B, Launay JM, Xavier RJ, Duboc H, Sokol H. Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. *Cell Metab*. 2018 Nov 6;28(5):737-749.e4. doi: 10.1016/j.cmet.2018.07.001.
 8. Sokol H, Leducq V, Aschard H, Pham HP, [...], Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. *Gut*. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746.
 9. Lamas B, Richard ML, Leducq V, Pham HP, [...], Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. *Nat Med*. 2016 Jun;22(6):598-605. doi: 10.1038/nm.4102.
 10. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A*. 2008 Oct 28;105(43):16731-6. doi: 10.1073/pnas.0804812105.

- Please note that the above information will be used for the introduction of speakers for the IMKASID 2025 website and announcements. Also, it will be provided to the session chairpersons before your lecture.

- Please complete this form (no more than 2 pages) and return it to the IMKASID 2025 secretariat by email, info@imkasid.kr.